RT Journal Article
T1 Targeted molecular iron oxide contrast agents for imaging atherosclerotic plaque
A1 Evans, Rhiannon
A1 Lavín Plaza, Begoña
A1 Phinikaridou, Alkystis
A1 Chooi, Kok Yean
A1 Mohri, Zahra
A1 Wong, Eunice
A1 Boyle, Joseph
A1 Krams, Rob
A1 Botnar, René
A1 Long, Nicholas
AB Cardiovascular disease remains a leading cause of death worldwide, with vulnerable plaque rupture the underlying cause of many heart attacks and strokes. Much research is focused on identifying an imaging biomarker to differentiate stable and vulnerable plaque. Magnetic Resonance Imaging (MRI) is a non-ionising and non-invasive imaging modality with excellent soft tissue contrast. However, MRI has relatively low sensitivity (micromolar) for contrast agent detection compared to nuclear imaging techniques. There is also an increasing emphasis on developing MRI probes that are not based on gadolinium chelates because of increasing concerns over associated systemic toxicity and deposits1. To address the sensitivity and safety concerns of gadolinium this project focused on the development of a high relaxivity probe based on superparamagnetic iron oxide nanoparticles for the imaging of atherosclerotic plaque with MRI. With development, this may facilitate differentiating stable and vulnerable plaque in vivo.
PB IvySpring
SN 2206-7418
YR 2020
FD 2020
LK https://hdl.handle.net/20.500.14352/97000
UL https://hdl.handle.net/20.500.14352/97000
LA eng
NO Evans RJ, Lavin B, Phinikaridou A, Chooi KY, Mohri Z, Wong E, Boyle JJ, Krams R, Botnar R, Long NJ. Targeted Molecular Iron Oxide Contrast Agents for Imaging Atherosclerotic Plaque. Nanotheranostics 2020; 4(4):184-194. doi:10.7150/ntno.44712. https://www.ntno.org/v04p0184.htm
NO British Heart Association
NO King’s College London
NO Imperial College London
DS Docta Complutense
RD 6 oct 2024